Adam Maass
Endocrinology, Diabetes & Metabolism · Springdale, ARNPI 1841258738
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $438,371 of the $502,367 with a category attached, or 87.3%. Lilly USA, LLC accounts for 60.5% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2019 at $212,640 and has fallen 94.9% since, to $10,847 in 2022. Among endocrinology, diabetes & metabolism clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,065 payments — averaging $471.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$304K
- Novo Nordisk$115K
- Boehringer Ingelheim$26K
- Chiasma, Inc.$14K
- AbbVie$13K
- Dexcom, Inc.$12K
- plus $19K from 25 others
What the payments were for
- Consulting fees$15,6643%
- Speaking & faculty fees$438,37187%
- Travel & lodging$37,1007%
- Food & beverage$11,1742%
- Education$580%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 658 | $303,770 |
| Novo Nordisk | 159 | $114,946 |
| Boehringer Ingelheim | 51 | $25,705 |
| Chiasma, Inc. | 16 | $14,005 |
| AbbVie | 30 | $12,972 |
| Dexcom, Inc. | 25 | $12,303 |
| Johnson & Johnson | 14 | $5,958 |
| Xeris Pharmaceuticals, Inc. | 9 | $5,414 |
| Insulet Corporation | 17 | $3,475 |
| Abbott | 17 | $849 |
| Eli Lilly | 1 | $746 |
| Sanofi-aventis U.S. LLC | 12 | $555 |
| Sanofi US Services Inc. | 1 | $350 |
| Amgen(2 entities) | 12 | $237 |
| Sanofi | 2 | $200 |
| Tandem Diabetes Care, Inc. | 5 | $163 |
| Antares Pharma, Inc. | 7 | $126 |
| AstraZeneca | 7 | $103 |
| Pfizer | 2 | $88 |
| Valeritas, Inc. | 1 | $84 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $65 |
| Zealand Pharma US, Inc. | 3 | $62 |
| Merck | 3 | $45 |
| Medtronic(2 entities) | 2 | $35 |
| Bayer | 2 | $30 |
| BD | 1 | $18 |
| Recordati_rare_diseases_inc. | 1 | $17 |
| Corcept Therapeutics | 1 | $13 |
| IBSA Pharma Inc. | 1 | $13 |
| Roche Diabetes Care, Inc. | 1 | $11 |
| Shire North American Group Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRULICITY$205,632
- JARDIANCE$105,242
- Ozempic$62,352
- RYBELSUS$27,948
- MYCAPSSA$13,723
- Synthroid$12,546
- Tresiba$11,472
- INVOKANA$5,500
- GVOKE PFS$5,348
- DEXCOM G6 TRANSMITTER$4,979
- DEXCOM G6 CGM SYSTEM$4,616
- Xultophy 100/3.6$3,375
- Omnipod$3,278
- DEXCOM CGM$2,460
- SOLIQUA 100/33$725
- FreeStyle Libre Pro$600
- TOUJEO$110
How this compares
$502,367 in reported general payments places this provider in the 95th percentile of 43 endocrinology, diabetes & metabolism providers in Arkansas.
See all endocrinology, diabetes & metabolism providers in Arkansas →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 25 | $25,751 |
| SynthroidLevothyroxine Sodium | 17 | $715 |
| Levothyroxine Sodium | 13 | $49 |
| Amiloride Hcl | 13 | $43 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $303,770 | $25,75125 claims |
| AbbVieSynthroid | $12,972 | $71517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 43 endocrinology, diabetes & metabolism providers in Arkansas.
Other endocrinology, diabetes & metabolism in Springdale
- Richard GriffithsLittle Rock$925K
- Catherine KilpatrickFayetteville$690K
- James ThrasherLittle Rock$349K
- Kevin GanongJonesboro$131K
- Cory GambleFort Smith$112K
- Chitharanjan DuvoorJonesboro$76K
- Richard RappLittle Rock$47K
- Shunzhong BaoLittle Rock$40K
- Jason DailyFayetteville$35K
- Daryl BurrowsHot Springs$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.